Cognition Therapeutics (CGTX) presented biomarker results from the Phase 2 SHINE study of zervimesine in mild-to-moderate Alzheimer’s disease ...

This protein, which can be measured with a blood test, has emerged as an indicator of Alzheimer’s disease pathology. Analysis of this low-p-Tau217 subgroup was defined in the SHINE study design in ...

SHINE研究检测了轻度至中度阿尔茨海默病患者的血液生物标志物，包括神经丝轻链、胶质纤维酸性蛋白、淀粉样β蛋白和tau蛋白。Hamby博士的演讲将重点介绍接受zervimesine治疗的参与者与安慰剂组相比，这些生物标志物的变化。结合先前观察到的认知和功能益处，这些发现旨在提供对该药物效果更全面的了解。

Investing.com — 周一，H.C. Wainwright分析师调整了对Cognition Therapeutics (NASDAQ: CGTX )的财务展望，将12个月目标价从此前的6美元下调至5美元，同时维持对该股的"买入"评级。该股目前交易价格为0.46美元，年初至今下跌35%，过去一年下跌75%。此次重新评估是在Cognition ...

Despite a significant net loss, Cognition Therapeutics Inc (CGTX) emphasizes promising clinical developments and strategic resource allocation to drive future growth.

Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) had its price target lowered by equities researchers at HC Wainwright ...

Q4 2024 Earnings Call Transcript March 20, 2025 Cognition Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

COGNITION THERAPEUTICS ($CGTX) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.17 per share, missing estimates of -$0. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to ...